|
|
|
|
Vol. 54, Issue 6, 1088-1096, December 1998
Department of Cellular and Molecular Biology, Centre de Recherche
Pierre Fabre, 81106 Castres Cédex, France
The 5-hydroxytryptamine (5-HT)1B/1D receptor subtypes are
involved in the regulation of 5-HT release and have gained particular interest because of their apparent role in migraine. Although selective
antagonists for both receptor subtypes recently have been developed,
the receptor domains involved in the pharmacological specificity of
these antagonists are defined poorly. This was investigated with a
chimeric 5-HT1B/1D receptor analysis and using ketanserin
as a selective antagonist of h5-HT1D
(h5-HT1D)
Ki = 24-27 nM)
as opposed to h5-HT1B
(Ki = 2193-2902
nM) receptors. A domain of the h5-HT1D
receptor encompassing the second extracellular loop and the fifth
transmembrane domain is necessary and sufficient to promote higher
affinity binding (Ki = 65-115
nM) for ketanserin to the h5-HT1B
receptor. The same domain of the h5-HT1B receptor, when
exchanged in the h5-HT1D receptor, abolished high affinity
binding of ketanserin (Ki = 364-1265 nM). A similar observation was made with the
antagonist ritanserin and seems specific because besides the unmodified
binding affinities for 5-HT and zolmitriptan, only minor modifications (2-4-fold) were observed for the agonists L 694247 and sumatriptan and
the antagonists GR 127935 and SB 224289. Generating point mutations of
divergent amino acids compared with the h5-HT1B receptor did not demonstrate a smaller peptide region related to a significant modification of ketanserin binding. The antagonists ketanserin and
ritanserin are likely to bind the h5-HT1D receptor by its second extracellular loop, near the exofacial surface of the fifth transmembrane domain, or both.
This article has been cited by other articles:
![]() |
D. Yin, S. Gavi, H.-y. Wang, and C. C. Malbon Probing Receptor Structure/Function with Chimeric G-Protein-Coupled Receptors Mol. Pharmacol., June 1, 2004; 65(6): 1323 - 1332. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Shi and J. A. Javitch The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice PNAS, January 13, 2004; 101(2): 440 - 445. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Piascik and D. M. Perez alpha 1-Adrenergic Receptors: New Insights and Directions J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 403 - 410. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Brys, K. Josson, M. P. Castelli, M. Jurzak, P. Lijnen, W. Gommeren, and J. E. Leysen Reconstitution of the Human 5-HT1D Receptor-G-Protein Coupling: Evidence for Constitutive Activity and Multiple Receptor Conformations Mol. Pharmacol., June 1, 2000; 57(6): 1132 - 1141. [Abstract] [Full Text] |
||||
![]() |
D. J. J. Waugh, R. J. Gaivin, M. J. Zuscik, P. Gonzalez-Cabrera, S. A. Ross, J. Yun, and D. M. Perez Phe-308 and Phe-312 in Transmembrane Domain 7 Are Major Sites of alpha 1-Adrenergic Receptor Antagonist Binding. IMIDAZOLINE AGONISTS BIND LIKE ANTAGONISTS J. Biol. Chem., June 29, 2001; 276(27): 25366 - 25371. [Abstract] [Full Text] [PDF] |
||||